Intrabony Defects Management Using Growth Factor Enhanced Matrix Versus Platelet Rich Fibrin Utilizing Minimally Invasive Surgical Technique. A Randomized Clinical and Radiographic Trial.
Twenty-one intra-bony defects in fifteen systemically healthy patients with moderate to severe chronic periodontitis were randomly classified into 3 groups, 7 sites each. Group І treated by MIST alone, group ІІ treated by MIST + ethylenediamine-tetraaceticacid (EDTA) + PRF and group III treated by MIST + EDTA + GEM 21S. The clinical parameters including probing pocket depth (PPD), clinical attachment level (CAL) and bleeding on probing (BOP), were recorded at baseline, 3, 6 and 9 months post-surgery. Cone beam computed tomography (CBCT) was performed at baseline and 9 months post-surgery to evaluate bone level and bone density
efficacy of autologous concentrated growth factor enriched bone graft matrix in magnification assisted treatment of periodontal intrabony defects : A randomized controlled clinical and radiographic study
After a loss of a tooth, alveolar bone resorption is immutable, leaving the area devoid of sufficient bone quality and mass for a successful and satisfactory implant or any other dental treatment. To treat this problem of irreversible bone loss, bone grafting is the primary solution and a well-accepted technique. The use of bone grafting procedures has increased in recent years. This review is about the various bone grafting techniques and best-situated material available currently along with their trump cards and limitations. In the thorough discussion regarding bone grafting materials and their substitutes, one alloplastic material has shown unbeaten and the most satisfactory properties than any other material, "bicalcium phosphate" (BCP). BCP is a mixture of hydroxyapatite (HA) and beta-tricalcium phosphate (B-TCP) usually obtained through sintering calcium-deficient apatite (CDA) at or above 700°C or by other methods such as hydrolysis or precipitation. The review also shows comparative studies done to understand the effect, most adequate balance, and impact of ratios of HA/B-TCP on the properties, structure, and success rate of this material. The objective of the review is to enlighten the principal characteristic of the most likely used bone graft material presently, i.e., BCP. The most impeccable characteristic of BCP is its capability to osteointegrate, which results in a superior interface. This interface depicts a dynamic process that includes physicochemical reactions, crystal-protein interactions, cell and tissue colonization, and bone remodeling. BCP has certain essential properties that could be put forth as its advantage over any other substitute. These properties include bioactivity, osteointegration, osteoinduction, osteogenesis, and biodegradation, which are mostly governed by modifying the HA/B-TCP ratio. Other applications of BCP are feasible, such as in drug administration and scaffolds for tissue engineering.
2023-01-31·Journal of biomedical materials research. Part B, Applied biomaterials
Property and biological effects of the cuttlebone derived calcium phosphate particles, a potential bioactive bone substitute material.
Cuttlebone (CB) is a marine waste-derived biomaterial and a rich source of calcium carbonate for the biosynthesis of the calcium phosphate (CaP) particles. The current study aimed to synthesize CB derived biphasic calcium phosphate (CB-BCP) and investigate biological activity of the CB-CaP: hydroxyapatite (CB-HA), beta-tricalcium phosphate (CB-b-TCP) and biphasic 60:40 (w/w) HA/b-TCP (CB-BCP) with the human dental pulp stem cells (hDPSCs). The particles were synthesized using solid state reactions under mild condition and properties of the particles were compared with a commercial BCP as a reference material. Morphology, particle size, physicochemical properties, mineral contents, and the ion released patterns of the particles were examined. Then the particle/cell interaction, cell cytotoxicity and osteogenic property of the particles were investigated in the direct and indirect cell culture models. It was found that an average particles size of the CB-HA was 304.73 ± 4.19 nm, CB-b-TCP, 503.17 ± 23.06 nm and CB-BCP, 1394.67 ± 168.19 nm. The physicochemical characteristics of the CB-CaP were consistent with the HA, b-TCP and BCP. The highest level of calcium (Ca) was found in the mineral contents and the preincubated medium of the CB-BCP and traces of fluoride, magnesium, strontium, and zinc were identified in the CB-CaP. The cell cytotoxicity and osteogenic property of the particles were dose dependent. The particles adhered on cell surface and were internalized into the cell cytoplasm. The CB-BCP and CB-HA indirectly and directly promote osteoblastic differentiations of the hDPSCs in stronger levels than other groups. The CB-BCP and CB-HA were potential bioactive bone substitute materials.
Three-dimensionally printed biphasic calcium phosphate blocks with different pore diameters for regeneration in rabbit calvarial defects.
作者: Young-Wook Seo ; Jin-Young Park ; Da-Na Lee ; Xiang Jin ; Jae-Kook Cha ; Jeong-Won Paik ; Seong-Ho Choi
Biphasic calcium phosphate (BCP) is the most frequently used synthetic bone substitutes, which comprises a combination of hydroxyapatite (HA) and beta-tricalcium phosphate (b-TCP). Thanks to the recent advances in digital dentistry and three-dimensional (3D) printing technology, synthetic block bone substitutes can be customized to fit individual defect morphologies. The diameter of the pores can influence the rate of bone formation and material resorption. The aim of this study was to compare three-dimensionally printed biphasic calcium phosphate (BCP) block bone substitutes with different pore diameters (0.8-, 1.0-, and 1.2- mm) for use in the regeneration of rabbit calvarial defects.
Four circular defects were formed on the calvaria of ten rabbits. Each defect was randomly allocated to one of the following study groups: (i) control group, (ii) 0.8-mm group, (iii) 1.0-mm group, and (iv) 1.2-mm group. All specimens were postoperatively harvested at 2 and 8 weeks, and radiographic and histomorphometric analyses were performed on the samples.
Histologically, the BCP blocks remained unresorbed up to 8 weeks, and new bone formation occurred within the porous structures of the blocks. After the short healing period of 2 weeks, histomorphometric analysis indicated that new bone formation was significantly greater in the BCP groups compared with the control (p < 0.05). However, there were no significant differences between the groups with different pore diameters (p > 0.05). At 8 weeks, only the 1.0-mm group (3.42 ± 0.48 mm2, mean ± standard deviation) presented a significantly larger area of new bone compared with the control (2.26 ± 0.59 mm2) (p < 0.05). Among the BCP groups, the 1.0- and 1.2-mm groups exhibited significantly larger areas of new bone compared with the 0.8-mm group (3.42 ± 0.48 and 3.04 ± 0.66 vs 1.60 ± 0.70 mm2, respectively).
Within the limitations of this study, the BCP block bone substitutes can be applied to bone defects for successful bone regeneration. Future studies should investigate more-challenging defect configurations prior to considering clinical applications.
PRINCETON, N.J., Oct. 27, 2022 /PRNewswire/ -- Geistlich Pharma North America announced today the acquisition of Lynch Biologics, LLC, the developer and sole provider of GEM 21S®, the first recombinant growth factor product for use in oral regenerative surgery. This acquisition further strengthens the regenerative product portfolio of Geistlich and provides significant growth potential.
"We're delighted to welcome Lynch Biologics to our Geistlich family and to have the opportunity to work with Dr. Lynch"
Geistlich Acquires Lynch Biologics
"We are delighted to welcome Lynch Biologics to our Geistlich family and to have the opportunity to work with Dr. Lynch and his talented team that are so passionate and committed to developing products that make a difference in the field of regeneration. I couldn't be more excited about our future together," said Les Burrows, General Manager, Geistlich Pharma North America. "GEM 21S contributes to our expanding portfolio of regenerative solutions. This acquisition allows us to align with another organization that has the same beliefs, clinically proven products, and a commitment to ongoing research. This sets the stage for additional new products that support our mission to drive regeneration in oral surgery."
The combination of two regenerative leaders offers:
Expanded regenerative solutions for clinicians and their patients
A combined team of purpose-driven leaders and highly skilled experts
Strengthened product development, clinical research, and education on new regenerative technologies
A shared commitment to research, quality, and safety
"I am so excited to combine Lynch Biologics with Geistlich Pharma North America. We look forward to being a part of the Geistlich Pharma North America team, known for their tremendous professionalism, integrity, and commitment to improving care for patients," stated Sam Lynch, DMD, DMSC, CEO, Lynch Biologics. "I believe this is an exciting opportunity as we bring together the companies with the most widely used biologic and the world market leader in dental biomaterials, which is an ideal combination to serve our customers in the oral regenerative space. Equally, I am thrilled to expand our training and education capabilities, as well as continue our clinical research. Having played a small role in helping to launch Geistlich products in the US many years ago and now having the ability years later to work with this team to bring new cutting-edge technologies together is incredibly fulfilling for me personally."
"The acquisition of Lynch Biologics demonstrates our commitment to the clinicians and patients of the United States and further enhances our portfolio of innovative products used worldwide, said Dr. Ralf P. Halbach, Chief Executive Officer, Geistlich Pharma AG. "We have long admired the pioneering spirit of Dr. Sam Lynch and welcome Lynch Biologics into our family."
Following the close of this acquisition, in conjunction with the Geistlich team, Dr. Lynch will continue to support existing and new customers through best-in-class dental education and trainings, as well as assist in addressing any questions doctors may have regarding GEM 21S®. All operations will be seamlessly integrated, so Lynch Biologic customers can continue to conveniently order GEM 21S® online, call the same 1-800 number, and most importantly, receive the same personalized service. pH Partners served as the exclusive financial advisor to Lynch Biologics.
About Lynch Biologics
Lynch Biologics is a regenerative medicine and tissue engineering company supplying advanced biotechnology products that promote healing and tissue regeneration spearheaded by GEM 21S®, and other widely used regenerative products, for periodontal and oral and maxillofacial indications. Their products have been used to help millions of patients regenerate lost bone and soft tissues and continue to be among the most popular grafting products with our dental colleagues.
GEM 21S® Growth-factor Enhanced Matrix was developed utilizing innovative tissue engineering principles which combine a bioactive protein (highly purified recombinant human platelet-derived growth factor, rhPDGF-BB) with an osteoconductive matrix (beta tricalcium phosphate, β-TCP).
This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.
About Geistlich North America Inc.
Geistlich Pharma North America brings the leader in regenerative dentistry directly to the United States and Canada. For 171 years, our respected family-owned Swiss parent company, Geistlich Pharma AG, has pioneered technological advances that make regenerative treatment, with safe and naturally sourced biomaterials, the preferred choice for clinical predictability. Geistlich is the world market leader in regenerative dentistry1,2. All our products are investigated rigorously before being released on the market. Geistlich products have been tested and developed for use in various therapeutic areas, in collaboration with more than 100 universities and leading surgeons.
We consistently meet or exceed industry safety and quality standards and follow a continuous training program for our employees. Meeting international scientific standards is a core principle of Geistlich Biomaterials. Geistlich Bio-Oss® and Geistlich Bio-Gide® bone regeneration materials are the most researched products in regenerative dentistry worldwide1,2. Moreover, we are committed to guiding clinicians through regenerative education, whether though physical courses, webinars, or through our BIOBRIEF clinical case series.
These substantial efforts lead to a single goal – to provide the highest standard of product quality and safety to improve the patients' quality of life. For more information, please visit us on our website https://dental.geistlich-na.com, or connect and follow us on LinkedIn, Instagram and Facebook.